|
Dr. Behm's research interests include understanding the pathogenesis of intestinal inflammation, noninvasive imaging of the small and large intestine, and translational and clinical research studying potential new therapies for inflammatory bowel disease. He is currently studying the role of statins in decreasing intestinal inflammation in patients with Crohn's disease. Dr. Behm has recently initiated studies evaluating the use of contrast-enhanced ultrasound in patients with idiopathic IBD. He is part of the inflammatory bowel disease clinical group, which is dedicated to understanding the pathophysiology and improving the treatment of Crohn's disease and ulcerative colitis.
Selected Publications:
Behm BW, Bickston SJ . Medical management of Crohn's disease: Current therapies and recent advances. Exp Rev Clin Immunol 2006;2:109-120.
Behm BW, Bickston SJ. Efficacy of infliximab for luminal and fistulizing Crohn's disease and ulcerative colitis. Curr Treat Options Gastroenterol. 2007;10:171-7.
Behm BW. Bickston SJ. Tumor Necrosis Factor-Alpha Antibody for Maintenance of Remission in Crohn's Disease. Cochrane Database Syst Rev. 2009 Jan 23;(1):CD006893.
Behm BW, Bickston SJ. Humanized antibody to the alpha4beta7 integrin for the induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD007571.
|
